GLP-1R works through the combination of the endogenous ligand Glucagon-like peptide-1 (GLP-1) or exogenous agonists, which activate multiple intracellular signaling pathways that enhance insulin secretion, inhibit glucagon secretion, protect -cells from apoptosis, delay gastric emptying and increase satiety
For semaglutide alone, trials relating to cardiovascular disease (SELECT), kidney disease (FLOW) and heart failure (STEP) have announced positive results in the last 12 months
In this comprehensive article, we will explore what GLP-1 is, how it was discovered, where it is produced in the body, its effects and half-life, and why it has become the most promising target in pharmaceutical weight loss
Here's what you need to know if you'd like to take advantage of this opportunity
They then use their control over networks and formularies to steer the most profitable prescriptions to the pharmacies they themselves own
Well, for the first time in my career, there is a medication for weight loss that has some decent data and results behind it
